Union Textiles Minister Giriraj Singh on Sunday, 14 June 2026 shared an article arguing that India's pharmaceutical sector has evolved beyond the Make in India framework to embrace a new export identity — 'Made for the World' — signalling the ruling establishment's push to reposition Indian pharma as a global supply powerhouse.

Context

The minister's post, shared via the NaMo App, highlighted a piece contending that 'Make in India se aage badha Bharat ka pharma, Made for the World bana naya export mantra' — broadly translated as 'Indian pharma has moved beyond Make in India, with Made for the World becoming the new export mantra.' While Singh holds the Textiles portfolio, his amplification of a pharma-export narrative reflects the BJP government's broader Atmanirbhar Bharat communication strategy, in which senior ministers routinely champion cross-sectoral economic milestones.

India is already the world's largest supplier of generic medicines by volume, providing affordable drugs to both developing nations and regulated markets in the United States, Europe, and Africa. The country accounts for roughly 20 per cent of global generic medicine exports by volume, a position built over decades of investment in bulk drug manufacturing and formulations.

Policy Backdrop

The 'Made for the World' framing sits atop two foundational policy pillars. The first is the Make in India initiative, launched in September 2014, which set out to attract investment and expand domestic manufacturing capacity across sectors, including pharmaceuticals. The second is the Production Linked Incentive (PLI) scheme for pharmaceuticals, approved in 2020, which offered financial incentives to manufacturers scaling up output of critical bulk drugs and complex formulations.

Together, these schemes were designed to reduce import dependence on Active Pharmaceutical Ingredients (APIs) — many sourced from China — while simultaneously boosting export competitiveness. The PLI scheme in pharma has drawn significant domestic and foreign investment into greenfield and brownfield manufacturing facilities across states including Telangana, Gujarat, Himachal Pradesh, and Andhra Pradesh.

The rhetorical shift from 'Make in India' to 'Made for the World' reflects a maturation in government messaging: domestic manufacturing capacity, once the goal, is now treated as a given, with the emphasis moving firmly toward export market share and global supply chain integration.

Stakeholders and Impact

Indian pharma exporters and generic drug manufacturers stand to benefit most directly from sustained policy attention. Industry bodies representing bulk drug makers and formulation exporters have long sought streamlined regulatory pathways and trade agreements to access new markets, particularly in Africa, Southeast Asia, and Latin America.

For developing nations, India's export-oriented pharma posture carries humanitarian significance — affordable Indian generics underpin public health programmes in dozens of low- and middle-income countries. Any expansion of export capacity and market reach could further lower medicine costs globally. Domestically, the sector is a significant employer, particularly in pharmaceutical clusters in Hyderabad and Ahmedabad.

What's Next

The immediate policy calendar includes the review of ongoing PLI scheme disbursements and performance benchmarks, with outcomes expected to inform the next round of export promotion measures. Industry watchers will look to the upcoming Union Budget and any revisions to India's Foreign Trade Policy for concrete incentives aligned with the 'Made for the World' ambition.

As India deepens trade negotiations with the European Union and pursues bilateral agreements across the Global South, the pharmaceutical sector's export trajectory will serve as a key benchmark for whether the Atmanirbhar Bharat framework can deliver sustained global market gains — not just domestic self-reliance.